// App-Quantinova.ai

P261 : Continuing versus withdrawing ixekizumab in patients with PsA who achieved sustained minimal disease activity: results from the SPIRIT-P3 study

Researchers

Presenter

  • Laura C Coates

Principal Investigators

  • Sreekumar G Pillai

  • Lu Zhang

  • David Adams

  • Lisa Kerr

  • Maja Hojnik

  • Gaia Gallo

  • Ivo Valter

  • Hasan Tahir

  • Vinod Chandran

  • Philip Mease

  • Arthur Kavanaugh

Medical Centers

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Eli Lilly and Company, Eli Lilly and Company, Indianapolis, IN

  • Center for Clinical and Basic Research, Center for Clinical and Basic Research, Tallinn, ESTONIA

  • Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom

  • Immunology, University of Toronto, Toronto, ON, CANADA

  • Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

  • Department of Medicine, University of California, La Jolla, CA

Locations

  • United Kingdom

  • United States

  • Estonia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • LY2439821

  • Regain

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02584855

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved